AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 3.38 USD 2.74% Market Closed
Market Cap: 334.4m USD
Have any thoughts about
AC Immune SA?
Write Note

Income Statement

Earnings Waterfall
AC Immune SA

Revenue
41m CHF
Operating Expenses
-78.3m CHF
Operating Income
-37.3m CHF
Other Expenses
-2.6m CHF
Net Income
-39.9m CHF

Income Statement
AC Immune SA

Rotate your device to view
Income Statement
Currency: CHF
Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
41
N/A
65
+60%
39
-40%
39
+1%
45
+15%
22
-51%
23
+5%
25
+7%
6
-78%
5
-5%
20
+286%
20
-3%
21
+6%
22
+6%
7
-68%
81
+1 022%
80
-1%
111
+39%
111
-1%
48
-57%
48
0%
15
-68%
15
+1%
3
-78%
2
-38%
1
-54%
0
N/A
0
N/A
0
N/A
4
N/A
4
-1%
4
+1%
4
N/A
0
N/A
15
N/A
15
N/A
15
+5%
41
+165%
Operating Income
Operating Expenses
(20)
(20)
(21)
(22)
(24)
(29)
(34)
(37)
(39)
(40)
(43)
(46)
(50)
(54)
(57)
(59)
(62)
(63)
(66)
(71)
(71)
(76)
(77)
(75)
(76)
(77)
(79)
(81)
(82)
(79)
(75)
(74)
(71)
(69)
(68)
(71)
(76)
(78)
Selling, General & Administrative
(3)
(3)
(2)
(2)
(2)
(3)
(5)
(6)
(6)
(7)
(6)
(7)
(7)
(8)
(8)
(8)
(8)
(9)
(9)
(10)
(11)
(11)
(11)
(11)
(11)
(11)
(11)
(11)
(11)
(10)
(10)
(10)
(9)
(10)
(11)
(13)
(13)
(14)
Research & Development
(16)
(16)
(17)
(19)
(21)
(24)
(26)
(28)
(29)
(29)
(33)
(35)
(39)
(42)
(44)
(46)
(48)
(48)
(50)
(54)
(54)
(58)
(60)
(58)
(59)
(58)
(62)
(64)
(66)
(65)
(60)
(59)
(57)
(55)
(55)
(56)
(59)
(61)
Depreciation & Amortization
0
(0)
(0)
0
0
(0)
(0)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Operating Expenses
0
(0)
(1)
0
(2)
(2)
(3)
(4)
(4)
(4)
(4)
(4)
(4)
(4)
(5)
(5)
(6)
(6)
(6)
(6)
(7)
(6)
(6)
(6)
(7)
(8)
(6)
(5)
(4)
(3)
(5)
(5)
(4)
(4)
(3)
(2)
(3)
(3)
Operating Income
21
N/A
45
+114%
19
-58%
17
-8%
21
+21%
(7)
N/A
(11)
-56%
(13)
-19%
(33)
-166%
(35)
-5%
(23)
+35%
(26)
-16%
(29)
-13%
(32)
-9%
(50)
-56%
22
N/A
19
-15%
49
+161%
45
-9%
(23)
N/A
(24)
-4%
(61)
-154%
(61)
-1%
(71)
-16%
(74)
-4%
(76)
-2%
(79)
-4%
(81)
-2%
(82)
-1%
(75)
+8%
(71)
+6%
(70)
+2%
(67)
+4%
(69)
-3%
(54)
+22%
(56)
-5%
(60)
-7%
(37)
+38%
Pre-Tax Income
Interest Income Expense
0
1
2
1
2
(0)
3
2
(2)
(1)
0
(4)
0
0
(0)
(1)
(2)
(2)
(4)
(1)
(0)
(0)
(1)
0
0
4
6
5
6
2
0
0
0
1
(1)
2
(0)
(3)
Total Other Income
0
0
0
0
0
0
0
0
0
1
(4)
1
2
(0)
(1)
4
1
3
5
(2)
(1)
(1)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
21
N/A
46
+116%
20
-56%
18
-11%
22
+23%
(7)
N/A
(7)
-2%
(10)
-46%
(36)
-243%
(35)
+1%
(26)
+25%
(29)
-8%
(27)
+4%
(32)
-17%
(51)
-59%
24
N/A
18
-24%
50
+172%
45
-10%
(26)
N/A
(25)
+4%
(62)
-151%
(62)
0%
(71)
-15%
(74)
-5%
(71)
+4%
(73)
-2%
(75)
-3%
(76)
-1%
(73)
+3%
(71)
+3%
(69)
+2%
(67)
+4%
(68)
-2%
(54)
+21%
(55)
-1%
(61)
-11%
(40)
+34%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
Income from Continuing Operations
21
46
20
18
22
(7)
(7)
(10)
(36)
(35)
(26)
(29)
(27)
(32)
(51)
24
18
50
45
(26)
(25)
(62)
(62)
(71)
(74)
(71)
(73)
(75)
(76)
(73)
(71)
(69)
(67)
(68)
(54)
(55)
(61)
(40)
Net Income (Common)
21
N/A
46
+116%
20
-56%
18
-11%
22
+23%
(7)
N/A
(7)
-2%
(10)
-46%
(36)
-243%
(35)
+1%
(26)
+25%
(29)
-8%
(27)
+4%
(32)
-17%
(51)
-59%
24
N/A
18
-24%
50
+172%
45
-10%
(26)
N/A
(25)
+4%
(62)
-151%
(62)
0%
(71)
-15%
(74)
-5%
(71)
+4%
(73)
-2%
(75)
-3%
(76)
-1%
(73)
+3%
(71)
+3%
(69)
+2%
(67)
+4%
(68)
-2%
(54)
+21%
(55)
-1%
(61)
-11%
(40)
+34%
EPS (Diluted)
0.4
N/A
0.85
+113%
0.38
-55%
0.33
-13%
0.41
+24%
-0.13
N/A
-0.14
-8%
-0.18
-29%
-0.62
-244%
-0.61
+2%
-0.46
+25%
-0.5
-9%
-0.47
+6%
-0.49
-4%
-0.82
-67%
0.35
N/A
0.27
-23%
0.69
+156%
0.64
-7%
-0.37
N/A
-0.35
+5%
-0.86
-146%
-0.86
N/A
-0.98
-14%
-1.02
-4%
-0.98
+4%
-0.97
+1%
-0.89
+8%
-0.89
N/A
-0.88
+1%
-0.85
+3%
-0.82
+4%
-0.79
+4%
-0.81
-3%
-0.64
+21%
-0.54
+16%
-0.6
-11%
-0.41
+32%

See Also

Discover More